HK Innoen 'K-CAB', Annual Prescription Sales Surpass 100 Billion KRW

HK Innoen 'K-Cab Tablet' (Photo by HK Innoen)

[Asia Economy Reporter Lee Chun-hee] HK Innoen's gastroesophageal reflux disease (GERD) new drug 'K-CAB,' the 30th domestic new drug, has surpassed 100 billion KRW in annual prescription sales. This is the fastest achievement in history.

HK Innoen announced on the 17th that K-CAB's outpatient prescription sales last year reached 109.6 billion KRW, exceeding 100 billion KRW annually for the first time since its launch. This represents a 43.9% increase compared to 76.1 billion KRW the previous year, and it ranked first in prescription sales among all peptic ulcer drugs for two consecutive years.

Generally, when the annual outpatient prescription amount of domestic specialty drugs exceeds 10 billion KRW, it is considered a successful market entry, so surpassing 100 billion KRW, which is ten times that amount, is highly significant. Additionally, having exceeded 100 billion KRW in just three years since its launch in 2019, it set a record for the shortest time to reach this milestone.

Kwack Dal-won, CEO of HK Innoen, said, "Achieving 100 billion KRW in the shortest period for K-CAB is highly meaningful as it reflects recognition of the product's safety and efficacy by the medical community and patients. Moving forward, we will further strengthen K-CAB's market position as a blockbuster new drug through expanded indication research, differentiated clinical trials, and the development of various formulations."

HK Innoen plans to launch an orally disintegrating tablet in the first half of this year in addition to the existing tablets. Through this expanded product range, it is expected to further increase market share. In December last year, the company announced the results of a Phase 3 clinical trial for 'maintenance therapy after GERD treatment,' demonstrating efficacy and safety during long-term use, and aims to add new indications based on this within this year.

This content was produced with the assistance of AI translation services.